News thumbnail

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

For clinicians, the data point toward new treatment goals in viral hepatitis and primary biliary cholangitis (PBC), with other key findings concerning persistence, real-world spending, and inexpensive interventions in advanced liver disease. Phase 3 Hepatitis Delta Readouts Set Up a Competitive MarketChronic hepatitis delta virus (HDV) infection, which occurs only in people with hepatitis B, produced the meeting’s 2 pivotal-trial readouts. HDV RNA was undetectable in 79.2% of treated patients, and response rates were similar with and without cirrhosis. Virologic response in AZURE-1 was defined as undetectable HDV RNA or a reduction of at least 2 log 10 IU/mL; 17% of patients in each brelovitug arm had undetectable HDV RNA at week 24. Hepatitis B Functional Cure Moves From Trials to PracticeThe meeting followed the FDA’s October 20, 2026, approval of bepirovirsen (Hibsago; GSK), the first antisense oligonucleotide for chronic hepatitis B.

Late-breaking phase 3 results in hepatitis delta, the arrival of a finite-duration therapy for chronic hepatitis B, and new questions about the cost of metabolic dysfunction–associated steatohepatitis (MASH) treatment took center stage at The Liver Meeting 2026 , held November 5 to 9 in Denver, Colorado.1 The meeting’s late-breaking program included 42 abstracts, led by 13 in hepatitis B and 10 in metabolic dysfunction–associated steatotic liver disease and MASH, with 6 more in cholestatic and autoimmune liver diseases.

For clinicians, the data point toward new treatment goals in viral hepatitis and primary biliary cholangitis (PBC), with other key findings concerning persistence, real-world spending, and inexpensive interventions in advanced liver disease.

Phase 3 Hepatitis Delta Readouts Set Up a Competitive Market

Chronic hepatitis delta virus (HDV) infection, which occurs only in people with hepatitis B, produced the meeting’s 2 pivotal-trial readouts.

In the phase 3 ECLIPSE 1 trial ( NCT06903338 ), 124 adults across 10 countries, about 55% of whom had compensated cirrhosis, were randomly assigned 2:1 to monthly subcutaneous elebsiran plus tobevibart (Vir Biotechnology) or to delayed treatment starting at week 12.2 At week 48, 44.1% of patients in the immediate-treatment arm had undetectable HDV RNA plus alanine aminotransferase (ALT) normalization compared with 0% of the delayed-treatment arm at week 12 (difference, 44.1 percentage points; 95% CI, 32.6-55.0). HDV RNA was undetectable in 79.2% of treated patients, and response rates were similar with and without cirrhosis. All participants completed 48 weeks of treatment with no serious adverse events or discontinuations, although 43.4% had flu-like symptoms, mostly after the first dose.2 Vir plans to submit a regulatory package to the FDA in mid-2027, and its ECLIPSE 3 trial ( NCT07142811 ) is comparing the regimen head-to-head with bulevirtide-gmod (Hepcludex; Gilead Sciences).3

Brelovitug (Mirum Pharmaceuticals), a monoclonal antibody that binds hepatitis B surface antigen, met its primary end point in the phase 3 portion of AZURE-1 ( NCT06907290 ), which randomly assigned 153 treatment-naive patients at 29 sites in 11 countries to brelovitug 300 mg weekly, 900 mg every 4 weeks, or delayed treatment.4 At week 24, the primary end point of virologic response plus ALT normalization was met by 33 of 59 patients (56%) with weekly dosing and 29 of 65 (45%) with every-4-week dosing compared with 0 of 29 with delayed treatment (P < .001 for both). Virologic response in AZURE-1 was defined as undetectable HDV RNA or a reduction of at least 2 log 10 IU/mL; 17% of patients in each brelovitug arm had undetectable HDV RNA at week 24. No patients discontinued brelovitug because of adverse events.4

Because the 2 trials used different end point definitions and time points, their response rates cannot be compared directly. Mirum expects to file a biologics license application in the first half of 2027, pending results from its second phase 3 trial, AZURE-4 ( NCT06567782 ), which are expected in the fourth quarter of 2026.5

Both candidates would enter a market that bulevirtide opened in May 2026, when it received accelerated approval as the first FDA-approved therapy for chronic HDV infection.6 The American Association for the Study of Liver Diseases (AASLD) also published an Expert-Based Practice Opinion on HDV diagnosis and management during the meeting.7 Both trials were sponsored by the drug manufacturers, and the results have not yet been published in a peer-reviewed journal.

Hepatitis B Functional Cure Moves From Trials to Practice

The meeting followed the FDA’s October 20, 2026, approval of bepirovirsen (Hibsago; GSK), the first antisense oligonucleotide for chronic hepatitis B. It is approved with ongoing nucleos(t)ide analogue therapy in certain adults without cirrhosis, and 19% of treated patients maintained viral control with undetectable hepatitis B surface antigen 24 weeks after stopping all treatment.8 The FDA also authorized a Roche assay as a companion diagnostic for patient selection.8 The drug carries a boxed warning for serious liver reactions and low platelet counts. GSK has said its list price will be disclosed after pricing and reimbursement discussions with payers conclude.9

Several investigational approaches aimed at the same goal reported early data. Among participants who achieved functional cure with the antisense oligonucleotide AHB-137 in the AB-10-8004 follow-up study ( NCT07146100 ) and had data available, 16 of 17 (94.1%) maintained it at 6 months of follow-up.10 In the ELIMINATE-B study ( NCT06680232 ), the gene-editing therapy PBGENE-HBV produced undetectable pregenomic RNA in 10 of 11 patients who were negative for hepatitis B antigen and had detectable levels at baseline, although average durability was 5 months and follow-up is ongoing.11

MASH Pipeline and Real-World Persistence

In the MK-6024-013 phase 2b trial ( NCT05877547 ) of 381 participants with stage F2 or F3 fibrosis, published in The Lancet, the glucagon-like peptide-1/glucagon receptor coagonist efinopegdutide (Merck) produced MASH resolution without worsening of fibrosis at 52 weeks in 56% to 63% of participants across 3 doses compared with 13% with placebo and 53% in an open-label reference arm of semaglutide 2.4 mg (Wegovy; Novo Nordisk).12,13 In the RECLAIM phase 2 trial ( NCT06987513 ), the glucagon/glucagon-like peptide-1 dual agonist pemvidutide (Altimmune) reduced heavy drinking days in patients with alcohol use disorder compared with placebo.14

For payers, persistence emerged as a cost driver. In a Markov-based model of 80,000 commercial health plan beneficiaries, 24 of every 100 members with MASH who were eligible for semaglutide remained on treatment through 72 weeks, and the authors estimated approximately $1.3 million in excess medical and pharmacy costs for each patient who responded to the optimal dose.15

Separate real-world analyses of pharmacy and claims data presented at the meeting and reported by The American Journal of Managed Care® (AJMC®) found 62.2% to 72.4% of patients remained on resmetirom (Rezdiffra; Madrigal Pharmaceuticals) at 12 months, although those studies used different methods and cannot be directly compared with the semaglutide model.16

Low-Cost Strategies in Cirrhosis and Alcohol-Associated Hepatitis

© All Rights Reserved.